234 related articles for article (PubMed ID: 36713427)
1. Chemo-immunoablation of solid tumors: A new concept in tumor ablation.
Meng L; Wei Y; Xiao Y
Front Immunol; 2022; 13():1057535. PubMed ID: 36713427
[TBL] [Abstract][Full Text] [Related]
2. Study of epirubicin sustained-release chemoablation in tumor suppression and tumor microenvironment remodeling.
Meng L; Wang Z; Hou Z; Wang H; Zhang X; Zhang X; He X; Zhang X; Qin B; Li J; Zhang Z; Xue X; Wei Y
Front Immunol; 2022; 13():1064047. PubMed ID: 36605217
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy.
Guo Y; Hu P; Shi J
J Am Chem Soc; 2024 Apr; 146(15):10217-10233. PubMed ID: 38563421
[TBL] [Abstract][Full Text] [Related]
4. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy.
Japir AAMM; Ke W; Li J; Mukerabigwi JF; Ibrahim A; Wang Y; Li X; Zhou Q; Mohammed F; Ge Z
J Control Release; 2021 Nov; 339():418-429. PubMed ID: 34662586
[TBL] [Abstract][Full Text] [Related]
5. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
7. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Immunotherapy for Early-stage Solid Tumors.
Hong WX; Haebe S; Lee AS; Westphalen CB; Norton JA; Jiang W; Levy R
Clin Cancer Res; 2020 Jul; 26(13):3091-3099. PubMed ID: 32071116
[TBL] [Abstract][Full Text] [Related]
9. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
10. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.
Chavez M; Silvestrini MT; Ingham ES; Fite BZ; Mahakian LM; Tam SM; Ilovitsh A; Monjazeb AM; Murphy WJ; Hubbard NE; Davis RR; Tepper CG; Borowsky AD; Ferrara KW
Theranostics; 2018; 8(13):3611-3628. PubMed ID: 30026870
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.
Huang CP; Liu LC; Chang CC; Wu CC; Shyr CR
Cancer Lett; 2022 Oct; 545():115478. PubMed ID: 35902043
[TBL] [Abstract][Full Text] [Related]
12. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
14. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.
Zhang N; Li Z; Han X; Zhu Z; Li Z; Zhao Y; Liu Z; Lv Y
Front Immunol; 2021; 12():811726. PubMed ID: 35069599
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy.
Yu X; Wang X; Yamazaki A; Li X
J Mater Chem B; 2022 May; 10(19):3637-3647. PubMed ID: 35439801
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
[TBL] [Abstract][Full Text] [Related]
17. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
18. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
[TBL] [Abstract][Full Text] [Related]
19. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
20. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
